Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
675 stopped studies mapped to Digestive System Adenocarcinoma and descendants · 93% state a reason
Over the 675 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT05109052 | Trial of PXS-5505 Combined With First Line Atezolizumab Plus Bevacizumab For Treating… | Phase 1 / Phase 2 | withdrawn | Nov 5, 2021 | University of Rochester | no accrual of eligible participants | Enrollment / accrual |
| NCT03970616 | A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced…(DEDUCTIVE) | Phase 1 / Phase 2 | terminated | May 31, 2019 | AVEO Pharmaceuticals, Inc. | The study was terminated due to regulatory approval of newer therapeutic options and slower than… | Enrollment / accrual |
| NCT03722498 | Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE | Phase 2 | withdrawn | Oct 29, 2018 | Sun Yat-sen University | No patients join | Other (stated, no rule matched) |
| NCT02530437 | Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With… | Phase 1 / Phase 2 | terminated | Aug 21, 2015 | M.D. Anderson Cancer Center | The sponsor sold the drug TALADEGIB to another company during the trial and thereafter no drug was… | Sponsor / business decision |
| NCT03591965 | Dual TORC1/TORC2 Inhibitor ATG-008 (CC-223) in HBV Positive Advanced Hepatocellular… | Phase 2 | terminated | Jul 19, 2018 | Antengene Therapeutics Limited | Based on the adjustment of clinical research and development strategy，sponsor decided to terminate… | Sponsor / business decision |
| NCT00303628 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III… | Phase 3 | terminated | Mar 17, 2006 | ECOG-ACRIN Cancer Research Group | The study was terminated before reaching its accrual goal due to slow accrual. | Enrollment / accrual |
| NCT05564338 | Efficacy and Safety of Sitravatinib Plus Tislelizumab or Placebo Plus Tislelizumab Versus… | Phase 3 | withdrawn | Oct 3, 2022 | BeiGene | Study has voluntarily discontinued due to a change in the company-level development strategy and is… | Safety / toxicity |
| NCT05886257 | Candonilimab Plus Bevacizumab for Patients With Advanced HCC Who Progressed on A+T | Phase 2 | withdrawn | Jun 2, 2023 | Shi Ming | Protocol adjustment | Other (stated, no rule matched) |
| NCT05375604 | A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma… | Phase 1 | terminated | May 16, 2022 | Codiak BioSciences | Company Bankruptcy | Sponsor / business decision |
| NCT02344810 | C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating… | Phase 1 / Phase 2 | withdrawn | Jan 26, 2015 | Eastern Cooperative Oncology Group | The study did not open to accrual. No start date and no completion dates. | Enrollment / accrual |
| NCT05039736 | A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR… | Phase 2 | withdrawn | Sep 10, 2021 | M.D. Anderson Cancer Center | 0 participants accrued | Enrollment / accrual |
| NCT02174575 | Anesthetic Agents and Acute Kidney Injury After Liver Resection Surgery | Phase 4 | withdrawn | Jun 25, 2014 | Tokyo Medical and Dental University | I retired my post before enrollment | Enrollment / accrual |
| NCT03662841 | Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma | N/A | terminated | Sep 10, 2018 | Chinese University of Hong Kong | poor patient accrual | Enrollment / accrual |
| NCT03808766 | A Study on the Angioarchitecture of Hepatocellular Carcinoma | N/A | terminated | Jan 18, 2019 | Chinese University of Hong Kong | Poor patient accrual | Enrollment / accrual |
| NCT05249569 | Study of Bavituximab, Axitinib, and Avelumab in Advanced Hepatocellular Carcinoma | Phase 2 | terminated | Feb 21, 2022 | University of Texas Southwestern Medical Center | Sponsor pulled support for one of the study drugs. | Other (stated, no rule matched) |
| NCT02376699 | Safety Study of SEA-CD40 in Cancer Patients | Phase 1 | terminated | Mar 3, 2015 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects… | Phase 1 | suspended | Dec 2, 2020 | Bellicum Pharmaceuticals | Due to a Dose Limiting Toxicity in another sister trial with same technology. | Safety / toxicity |
| NCT04852367 | PanDox: Targeted Doxorubicin in Pancreatic Tumours(PanDox) | Phase 1 | withdrawn | Apr 21, 2021 | University of Oxford | Lack of recruitment | Enrollment / accrual |
| NCT04150874 | Contrast-Enhanced Ultrasound for the Evaluation of Changes in Tumor Blood Flow… | Early Phase 1 | terminated | Nov 5, 2019 | H. Lee Moffitt Cancer Center and Research Institute | Slow Accrual | Enrollment / accrual |
| NCT04442581 | Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer | Phase 2 | terminated | Jun 22, 2020 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT03019588 | Efficacy and Safety Study of Pembrolizumab (MK-3475) Versus Paclitaxel in Asian… | Phase 3 | terminated | Jan 12, 2017 | Merck Sharp & Dohme LLC | Business Reasons | Sponsor / business decision |
| NCT04777708 | BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer | Early Phase 1 | terminated | Mar 2, 2021 | Jonsson Comprehensive Cancer Center | Withdrawn by sponsor | Other (stated, no rule matched) |
| NCT04042480 | A Study of SGN-CD228A in Advanced Solid Tumors | Phase 1 | terminated | Aug 2, 2019 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT05157451 | Y-90 Versus SBRT for Inoperable HCC | Phase 2 | withdrawn | Dec 15, 2021 | OHSU Knight Cancer Institute | Not feasible at this time. | Other (stated, no rule matched) |
| NCT04635527 | A Study on the Safety and Effectiveness of IBI318 Combined With Conventional TACE (cTACE)… | Phase 1 | terminated | Nov 19, 2020 | Innovent Biologics (Suzhou) Co. Ltd. | Due to the company's development strategy adjustment ，Innovent Bioligics decided not to continue… | Sponsor / business decision |
| NCT04649671 | The Effect of Mobile Health-based Exercise on Hepatocellular Carcinoma Patients With… | N/A | terminated | Dec 2, 2020 | Samsung Medical Center | Difficulty in recruitment and deficit of research fund | Enrollment / accrual |
| NCT02899325 | FDGal PET/CT to Detect Hepatocellular Carcinoma | — | withdrawn | Sep 14, 2016 | British Columbia Cancer Agency | PIs will not pursue trial due to staff and time constraints | Other (stated, no rule matched) |
| NCT04965714 | Nivolumab and ADI-PEG 20 Before Surgery for the Treatment of Resectable Liver Cancer | Phase 2 | withdrawn | Jul 16, 2021 | M.D. Anderson Cancer Center | 0 patient accrual | Enrollment / accrual |
| NCT05592197 | Safety and Efficacy of Radiation Plus TACE and Lenvatinib in Advanced HCC With PVTT | N/A | withdrawn | Oct 24, 2022 | Sun Yat-sen University | This is a sub-study of another one. | Other (stated, no rule matched) |
| NCT03236649 | The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced… | Phase 3 | terminated | Aug 2, 2017 | Beijing Shenogen Biomedical Co., Ltd | Because the clinical development plan has been changed. | Other (stated, no rule matched) |
| NCT03240679 | Endoscopic Mucosal Resection and Cellular Matrix | N/A | terminated | Aug 7, 2017 | Mayo Clinic | Difficulty obtaining investigational product and study support. | Other (stated, no rule matched) |
| NCT04510285 | A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+… | Phase 2 | terminated | Aug 12, 2020 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT04077372 | Assessment of a Serious Illness Conversation Guide (SICG) in Advanced Gastro-Intestinal… | N/A | terminated | Sep 4, 2019 | Stanford University | Covid-19 | COVID-19 / pandemic |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and…(MATILDA) | Phase 2 | withdrawn | Jun 11, 2019 | Gustave Roussy, Cancer Campus, Grand Paris | Similar clinical trials showed not very encouraging results, which made us decide, after several… | Other (stated, no rule matched) |
| NCT05628545 | Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells | Phase 1 / Phase 2 | withdrawn | Nov 28, 2022 | Guangdong GD Kongming Biotech LLC | COVID1-19 pandemic | COVID-19 / pandemic |
| NCT03582618 | CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma | Phase 2 | terminated | Jul 11, 2018 | TaiRx, Inc. | The study has been terminated due to slow enrollment | Enrollment / accrual |
| NCT04044430 | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E… | Phase 1 | terminated | Aug 5, 2019 | University of California, San Francisco | Sponsor funding | Funding |
| NCT01433016 | Detection of Hepatocellular Carcinoma (HCC) With Octanoate Breath ID Test Compared to MRI(OBT for HCC) | Phase 2 | terminated | Sep 13, 2011 | Meridian Bioscience, Inc. | Due to budgetary issues, the company has decided to focus on other applications at this stage. | Funding |
| NCT01381211 | Transarterial RAdioembolization Versus ChemoEmbolization for the Treatment of…(TRACE) | Phase 2 | terminated | Jun 27, 2011 | University Hospital, Ghent | based on interim analysis results | Efficacy / futility |
| NCT04642690 | Nitrates and IL-8 in Barrett's Esophagus | — | terminated | Nov 24, 2020 | Mayo Clinic | could not collect adequate samples | Other (stated, no rule matched) |
| NCT03781960 | Abemaciclib and Nivolumab for Subjects With Hepatocellular Carcinoma | Phase 2 | terminated | Dec 20, 2018 | Abramson Cancer Center at Penn Medicine | Safety letter from sponsor | Safety / toxicity |
| NCT04178642 | The Impact on Hepatic Recurrence After Adjuvant Chemotherapy With Intraarterial Infusion…(LIDA-ADJ) | Phase 2 | withdrawn | Nov 26, 2019 | University Hospital, Montpellier | no participants enrolled | Enrollment / accrual |
| NCT05327738 | Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of… | Phase 2 | withdrawn | Apr 14, 2022 | OHSU Knight Cancer Institute | Due to inadequate funding. This trial may open as a new clinical trial at a later date, pending… | Funding |
| NCT05380557 | ARTEMIS: Study of Patients With Early Stage Pancreatic Cancer Who Have Undergone Genetic…(ARTEMIS) | — | terminated | May 19, 2022 | Invitae Corporation | Low site engagement and accrual | Enrollment / accrual |
| NCT04400903 | Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer | — | terminated | May 26, 2020 | OHSU Knight Cancer Institute | Slow accrual | Enrollment / accrual |
| NCT01167374 | Carbon Ion Radiotherapy for Hepatocellular Carcinoma(PROMETHEUS-01) | N/A | terminated | Jul 22, 2010 | University Hospital Heidelberg | Slow recruitment rate | Enrollment / accrual |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | Phase 2 | terminated | Oct 3, 2018 | Abramson Cancer Center at Penn Medicine | Terminated due to slow enrollment and lack of efficacy | Efficacy / futility |
| NCT02415036 | Melphalan for Use With the Hepatic Delivery System Treatment in Patients With… | Phase 2 | terminated | Apr 14, 2015 | Delcath Systems Inc. | Limited enrollment | Enrollment / accrual |
| NCT05093608 | SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced… | Phase 1 | terminated | Oct 26, 2021 | H. Lee Moffitt Cancer Center and Research Institute | Loss of funding | Funding |
| NCT03781778 | Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors | Phase 2 | terminated | Dec 20, 2018 | Fred Hutchinson Cancer Center | Terminated due to expiration of funding | Funding |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Jul 13, 2023source: clinicaltrials